Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.66 |
| ▸ | FLT1 | P17948 | 15/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.66 |
| ▸ | KIT | P10721 | 7/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HLA-A | P04439 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | STK3 | Q13188 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955485 | 0.89 | FLT1 (0.52) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955418 | 0.88 | KDR (0.52) | KDRFLT1PDGFRBKITALDH1A1 | |
| SCHEMBL13955411 | 0.85 | KDR (0.48) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955494 | 0.85 | FLT1 (0.50) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL2201541 | 0.84 | FLT1 (0.64) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955486 | 0.84 | FLT1 (0.64) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955592 | 0.83 | CYP1A2 (0.46) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955571 | 0.83 | KDR (0.48) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL13955585 | 0.83 | KDR (0.55) | KDRFLT1PDGFRBKITHTT | |
| SCHEMBL13955419 | 0.83 | KDR (0.48) | KDRFLT1PDGFRBKITALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | claimed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | claimed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | claimed |
| US-20080207658-A1 | Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors | MANLEY PAUL W | 2008-08-28 | — | — | US | claimed |
| EP-1885352-A2 | COMBINATIONS COMPRISING JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | Novartis AG (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1863491-A1 | PHARMACEUTICAL COMBINATION OF BCR-ABL AND RAF INHIBITORS | Novartis AG (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2006089781-A1 | PHARMACEUTICAL COMBINATION OF BCR-ABL AND RAF INHIBITORS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | claimed |
| WO-2006056399-A2 | COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | claimed |
| US-6608071-B2 | Angiogenesis inhibitors as antitumor agents | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | claimed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | disclosed |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | disclosed |
| CN-101080227-B | Combinations of therapeutic agents for treating cancer | NOVARTIS AG | 2011-08-31 | — | — | CN | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| WO-2006089781-A1 | PHARMACEUTICAL COMBINATION OF BCR-ABL AND RAF INHIBITORS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006056399-A2 | COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
| EP-1603566-A1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | Novartis AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005005990-A2 | INVERSE LABELING METHOD FOR THE RAPID IDENTIFICATION OF MARKER TARGET PROTEINS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004080464-A1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040106150-A1 | Inverse labeling method for the rapid identification of marker/target proteins | WANG YINGQI KAREN (US) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | KDR 123/4885FLT1 26/4885PDGFRB 40/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | KDR 123/4885FLT1 26/4885PDGFRB 40/4885 |
| US-20080207658-A1 | Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors | BRAF, BCR, ABL1 | KDR 214/4885FLT1 237/4885PDGFRB 44/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | KDR 74/4885FLT1 25/4885PDGFRB 67/4885 |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | BRAF, RAF1, MTOR | KDR 539/4885FLT1 812/4885PDGFRB 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.